Holen Sie sich die Stockscreener-App
72.12
0.82%
0.59
Handel nachbörslich:
75.06
2.94
+4.08%
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
Corcept Therapeutics (CORT) Seeks EMA Approval for Relacorilant in Cancer Treatment - GuruFocus
Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Stock Titan
Analyzing Corcept Therapeutics Incorporated with risk reward ratio chartsJuly 2025 Setups & Detailed Earnings Play Alerts - newser.com
Corcept Therapeutics Incterminates distribution agreement with Optime CareSEC filing - MarketScreener
Corcept Therapeutics Incorporated $CORT Holdings Trimmed by Aberdeen Group plc - MarketBeat
What momentum indicators show for Corcept Therapeutics Incorporated stockQuarterly Market Summary & Risk Controlled Stock Pick Alerts - newser.com
Is Corcept Therapeutics Incorporated stock positioned well for digital economyEarnings Summary Report & Weekly Market Pulse Updates - newser.com
What moving averages say about Corcept Therapeutics Incorporated2025 Biggest Moves & AI Powered Buy and Sell Recommendations - newser.com
Technical analysis overview for Corcept Therapeutics Incorporated stockPortfolio Growth Summary & High Accuracy Trade Alerts - newser.com
Volume spikes in Corcept Therapeutics Incorporated stock – what they mean2025 Retail Activity & Safe Capital Growth Tips - newser.com
How Corcept Therapeutics Incorporated stock compares to growth peers2025 Year in Review & Stock Portfolio Risk Control - newser.com
Corcept Therapeutics (CORT) Stock Analysis: A Promising 82.87% Upside in the Biotech Sector - DirectorsTalk Interviews
Momentum divergence signals in Corcept Therapeutics Incorporated chart2025 Retail Activity & AI Driven Price Forecasts - newser.com
How sentiment analysis helps forecast Corcept Therapeutics IncorporatedJuly 2025 Trends & Stepwise Trade Signal Guides - newser.com
Corcept Therapeutics (CORT) Is Down 16.1% After Distribution Shift and Insider Selling—What's Changed - Yahoo Finance
Maryland State Retirement & Pension System Has $2.37 Million Stock Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Insider William Guyer Sells 20,000 Shares - MarketBeat
Corcept Therapeutics (CORT) Sees Significant Drop of 13.3% - GuruFocus
Why Corcept (CORT) Shares Are Falling Today - The Globe and Mail
3 Profitable Stocks That Concern Us - The Globe and Mail
Corcept Therapeutics (CORT) Shares Drop as Optime Care Ends Dist - GuruFocus
Corcept Therapeutics (CORT) Adjusts Korlym Distribution Strategy - GuruFocus
Corcept Therapeutics (CORT) Shares Drop Amid Market Activity - GuruFocus
Corcept Therapeutics (CORT) Rating Reiterated as 'Buy' by HC Wai - GuruFocus
Corcept Therapeutics' (CORT) "Hold (C)" Rating Reiterated at Weiss Ratings - MarketBeat
Insider Sell: William Guyer Sells 20,000 Shares of Corcept Thera - GuruFocus
Platinum-Resistant Ovarian Cancer Treatment Market Sees Momentum with Next-Generation Targeted Strategies | DelveInsight - The Malaysian Reserve
Corcept Therapeutics Incorporated stock trend outlook and recovery pathWeekly Profit Recap & Daily Volume Surge Signals - newser.com
Corcept Therapeutics (NASDAQ:CORT) Stock Price Down 4.9%Here's Why - MarketBeat
Corcept Therapeutics Board Member Resigns, Continues as Consultant - MSN
Pre-ESMO insights: Corcept on platinum-resistant ovarian cancer - pharmaphorum
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT) and Genmab (GMAB) - The Globe and Mail
Corcept's NDA for its hypercortisolism treatment gets FDA nod - MSN
1 Cash-Heavy Stock with Exciting Potential and 2 That Underwhelm - The Globe and Mail
Myasthenia Gravis Pipeline Outlook Report 2025: Novel Therapeutics, Clinical Advancements, and Opportunities - The Globe and Mail
'This isn't a dress rehearsal': Why the coming months could be big for a Peninsula drug company that has survived decades - The Business Journals
Truist Financial Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $135 - 富途牛牛
What Fibonacci levels say about Corcept Therapeutics Incorporated reboundWeekly Risk Report & AI Forecasted Entry and Exit Points - newser.com
Will Corcept Therapeutics Incorporated bounce back from current supportQuarterly Earnings Summary & Real-Time Volume Analysis - newser.com
Is a relief rally coming for Corcept Therapeutics Incorporated holdersJuly 2025 Weekly Recap & Free Safe Entry Trade Signal Reports - newser.com
QRG Capital Management Inc. Acquires 13,829 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Why Corcept Therapeutics Incorporated stock is seen as undervalued2025 Technical Overview & Real-Time Market Sentiment Alerts - newser.com
Visual analytics tools that track Corcept Therapeutics Incorporated performance2025 Bull vs Bear & Precise Swing Trade Entry Alerts - newser.com
Is Corcept Therapeutics Incorporated (HTD) stock undervalued by metricsJuly 2025 Short Interest & Low Risk Growth Stock Ideas - newser.com
Earnings Tell The Story For Corcept Therapeutics Incorporated (NASDAQ:CORT) As Its Stock Soars 27% - 富途牛牛
JSF Financial LLC Makes New Investment in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics (CORT): Evaluating Valuation After New Curant Health Partnership and Pipeline Progress - Yahoo Finance
Corcept Therapeutics (NASDAQ:CORT) Insider Joseph Douglas Lyon Sells 5,000 Shares - MarketBeat
Low-Volatility Stocks Underperforming: RSI, ADT, CORT AnalysisNews and Statistics - IndexBox
Here’s What Makes Corcept Therapeutics (CORT) an Attractive Investment? - Yahoo Finance
Synergy Asset Management LLC Raises Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Downgraded by Zacks Research to Strong Sell - MarketBeat
Public Employees Retirement System of Ohio Boosts Stock Holdings in Corcept Therapeutics Incorporated $CORT - Defense World
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):